The recent advent of targeted agents such as erlotinib and crizotinib has yielded dramatic short-term clinical responses in patients with specific oncogene mutations (e.g. mutant EGFR or EML4-ALK fusions) showing the benefit of developing molecular analyses of tumors to implement “precision medicine” for lung cancer [2-4]. The gene discussed is ALK; the disease is lung carcinoma.